NO20091864L - Forbindelser for inhibering av mitotisk progresjon - Google Patents

Forbindelser for inhibering av mitotisk progresjon

Info

Publication number
NO20091864L
NO20091864L NO20091864A NO20091864A NO20091864L NO 20091864 L NO20091864 L NO 20091864L NO 20091864 A NO20091864 A NO 20091864A NO 20091864 A NO20091864 A NO 20091864A NO 20091864 L NO20091864 L NO 20091864L
Authority
NO
Norway
Prior art keywords
compounds
mitotic progression
inhibiting mitotic
methods
inhibiting
Prior art date
Application number
NO20091864A
Other languages
English (en)
Other versions
NO343338B1 (no
Inventor
Christopher F Claiborne
Todd B Sells
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091864(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of NO20091864L publication Critical patent/NO20091864L/no
Publication of NO343338B1 publication Critical patent/NO343338B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser med formel (I) og fremgangsmåter for behandling av kreft. Spesielt tilveiebringer oppfinnelsen potente inhibitorer av Aurora A kinase, farmasøytiske sammensetninger omfattende forbindelsene og fremgangsmåter for anvendelse av forbindelsene for behandling av kreft.
NO20091864A 2006-11-16 2009-05-13 Forbindelser for inhibering av mitotisk progresjon og anvendelse derav, samt farmasøytisk sammensetning NO343338B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16
PCT/US2007/023948 WO2008063525A1 (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Publications (2)

Publication Number Publication Date
NO20091864L true NO20091864L (no) 2009-06-15
NO343338B1 NO343338B1 (no) 2019-02-04

Family

ID=39315133

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091864A NO343338B1 (no) 2006-11-16 2009-05-13 Forbindelser for inhibering av mitotisk progresjon og anvendelse derav, samt farmasøytisk sammensetning

Country Status (35)

Country Link
US (6) US8026246B2 (no)
EP (4) EP2497773B1 (no)
JP (3) JP5102839B2 (no)
KR (2) KR101342014B1 (no)
CN (2) CN101547924B (no)
AR (1) AR064246A1 (no)
AT (1) ATE556076T1 (no)
AU (1) AU2007322046B2 (no)
BR (1) BRPI0718803B8 (no)
CA (1) CA2669680C (no)
CL (1) CL2007003244A1 (no)
CR (3) CR10782A (no)
CY (1) CY1112828T1 (no)
DK (2) DK2086981T3 (no)
EA (1) EA015779B1 (no)
ES (3) ES2384123T3 (no)
GE (1) GEP20125459B (no)
HK (4) HK1134672A1 (no)
HR (2) HRP20120490T1 (no)
IL (1) IL198690A0 (no)
MA (1) MA30988B1 (no)
MX (3) MX348568B (no)
MY (1) MY153243A (no)
NO (1) NO343338B1 (no)
NZ (3) NZ597252A (no)
PH (1) PH12012502057B1 (no)
PL (2) PL2497772T3 (no)
PT (2) PT2086981E (no)
RS (2) RS53788B1 (no)
SG (2) SG176443A1 (no)
SI (2) SI2086981T1 (no)
TW (1) TWI401255B (no)
UA (1) UA94129C2 (no)
WO (1) WO2008063525A1 (no)
ZA (1) ZA200903279B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE381566T1 (de) 2004-05-14 2008-01-15 Millennium Pharm Inc Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
AR074487A1 (es) * 2008-12-05 2011-01-19 Millennium Pharm Inc Tiolactamas inhibidoras de proteinquinasas plk, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de trastornos proliferativos e inflamatorios, en particular cancer.
WO2010074724A1 (en) * 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CA2788774A1 (en) 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
ES2526671T3 (es) * 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
AR086656A1 (es) * 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
EP3236948A4 (en) * 2014-12-23 2018-10-03 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
US10221158B2 (en) 2015-09-09 2019-03-05 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
EP3347355B1 (en) 2015-09-09 2022-07-13 Icahn School of Medicine at Mount Sinai Heterotricyclic sulfonamides as anti-cancer agents
JP6591036B2 (ja) 2016-02-26 2019-10-16 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
AU2017233898B2 (en) 2016-03-15 2022-12-15 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for use in the treatment of solid tumors
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
US20240108618A1 (en) 2022-06-30 2024-04-04 Eli Lilly And Company Kras g12c inhibitor dosing regimens

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
FR2450833A1 (fr) 1979-02-07 1980-10-03 Hoffmann La Roche Derives de benzazepine
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CA2247453A1 (en) * 1996-03-08 1997-09-12 Joseph James Lewis Azolobenzazepine derivatives as neurologically active agents
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
AU744636B2 (en) * 1997-09-29 2002-02-28 Meiji Seika Pharma Co., Ltd. Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
EP1236712B1 (en) 1999-12-06 2008-08-06 Ajinomoto Co., Inc. Amidinophenylpyruvic acid derivative
ATE528303T1 (de) 2000-12-21 2011-10-15 Vertex Pharma Pyrazoleverbindungen als proteinkinasehemmer
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
NZ530741A (en) 2001-08-09 2006-08-31 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles as endothelin antagonists
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
ATE381566T1 (de) 2004-05-14 2008-01-15 Millennium Pharm Inc Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
US8153630B2 (en) 2004-11-17 2012-04-10 Miikana Therapeutics, Inc. Kinase inhibitors
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
CA2634787C (en) 2005-12-23 2014-10-21 Smithkline Beecham Corporation Azaindole inhibitors of aurora kinases
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
EP2944639A1 (en) 2015-11-18
CN101547924A (zh) 2009-09-30
MX343391B (es) 2016-11-04
KR101110458B1 (ko) 2012-03-13
EP2086981A1 (en) 2009-08-12
CR10782A (es) 2009-06-24
EA015779B1 (ru) 2011-12-30
US20110312943A1 (en) 2011-12-22
JP5102839B2 (ja) 2012-12-19
HK1217699A1 (zh) 2017-01-20
ES2528793T3 (es) 2015-02-12
UA94129C2 (ru) 2011-04-11
CN101547924B (zh) 2013-09-25
HK1134672A1 (en) 2010-05-07
PL2086981T3 (pl) 2012-09-28
KR20110113210A (ko) 2011-10-14
RS52313B (en) 2012-12-31
MA30988B1 (fr) 2009-12-01
PT2497772E (pt) 2015-02-05
ES2537451T3 (es) 2015-06-08
EP2944639B1 (en) 2017-01-04
ZA200903279B (en) 2010-07-28
RS53788B1 (en) 2015-06-30
AU2007322046A1 (en) 2008-05-29
CR20140544A (es) 2015-01-12
SI2086981T1 (sl) 2012-12-31
EP2497772A1 (en) 2012-09-12
JP2012006965A (ja) 2012-01-12
US8026246B2 (en) 2011-09-27
EP2497773A1 (en) 2012-09-12
SG10201503350TA (en) 2015-06-29
EP2497772B1 (en) 2014-10-29
TW200829589A (en) 2008-07-16
NZ611898A (en) 2015-01-30
HK1175777A1 (en) 2013-07-12
BRPI0718803A2 (pt) 2013-12-03
DK2086981T3 (da) 2012-08-06
US10836766B2 (en) 2020-11-17
SI2497772T1 (sl) 2015-03-31
ES2384123T3 (es) 2012-06-29
KR20090091173A (ko) 2009-08-26
CA2669680A1 (en) 2008-05-29
WO2008063525A1 (en) 2008-05-29
BRPI0718803B8 (pt) 2021-05-25
HRP20150047T1 (en) 2015-03-13
JP2014055166A (ja) 2014-03-27
BRPI0718803B1 (pt) 2020-11-17
GEP20125459B (en) 2012-03-26
AU2007322046B2 (en) 2012-04-05
US9765076B2 (en) 2017-09-19
US20190031662A1 (en) 2019-01-31
US20080167292A1 (en) 2008-07-10
PL2497772T3 (pl) 2015-05-29
MX348568B (es) 2017-06-20
US20110312942A1 (en) 2011-12-22
SG176443A1 (en) 2011-12-29
CL2007003244A1 (es) 2008-04-04
JP5452811B2 (ja) 2014-03-26
CA2669680C (en) 2012-04-10
US11958855B2 (en) 2024-04-16
ATE556076T1 (de) 2012-05-15
US20210214361A1 (en) 2021-07-15
CR20140154A (es) 2014-07-23
PH12012502057A1 (en) 2015-09-14
PH12012502057B1 (en) 2015-09-14
EA200970486A1 (ru) 2009-10-30
AR064246A1 (es) 2009-03-25
NZ577042A (en) 2012-03-30
IL198690A0 (en) 2010-02-17
US20150166545A1 (en) 2015-06-18
CY1112828T1 (el) 2016-02-10
HK1175778A1 (en) 2013-07-12
CN103483343B (zh) 2016-06-01
MY153243A (en) 2015-01-29
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
CN103483343A (zh) 2014-01-01
HRP20120490T1 (hr) 2012-07-31
NO343338B1 (no) 2019-02-04
EP2497773B1 (en) 2015-02-25
NZ597252A (en) 2013-06-28
EP2086981B1 (en) 2012-05-02
JP2010510215A (ja) 2010-04-02
DK2497772T3 (en) 2015-01-19
TWI401255B (zh) 2013-07-11
US9988384B2 (en) 2018-06-05
KR101342014B1 (ko) 2013-12-19

Similar Documents

Publication Publication Date Title
NO20091864L (no) Forbindelser for inhibering av mitotisk progresjon
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
IL178675A0 (en) Monocyclic heterocycles as kinase inhibitors
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
CY1113192T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου μεσω αναστολης της κινασης aurora
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
TNSN08227A1 (en) [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
NO20070681L (no) 2, 4, 6-Trisubstituterte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse i behandling av kreft
EA200800374A1 (ru) 1,4-дигидропиридин-конденсированные гетероциклы, способы их получения, применение и содержащие их композиции
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
MX2009004140A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
NO20076075L (no) 4-anilino-3-kinolinkarbonitriler for behandling av cancer
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors
UA95260C2 (ru) Производное 4-(3-аминопиразол)пиримидина и его применение для лечения злокачественного новообразования
CY1117072T1 (el) Ενωσεις αναστολης της μιτωτικης διαδικασιας